Perthera and Lazarex Cancer Foundation Announce Partnership to Advance Precision Oncology Initiatives

Holliston, MA // Perthera and Lazarex are matching and enrolling patients in clinical trials through Lazarex’s IMPACT and CARE programs, by utilizing Perthera’s treatment-matching Artificial Intelligence (AI) technology to advance precision medicine for cancer patients.

How Perthera is Using AI and Molecular Data to Bring Precision Medicine to Oncology

Perthera CEO Gary Gregory talks with DocWire News to explain how Perthera’s Precision Oncology Platform is transforming precision medicine in healthcare today, with proven results and advanced technology.

ASCO 2019 Poster Presentation Shows Improved Overall Survival for Advanced Pancreatic Cancer Patients Enrolled in the Know Your Tumor Program

Initial results from the KYT program demonstrated that 27% of pancreatic cancer patients harbor highly actionable molecular alterations, defined as biomarkers that predict for a high response rate to appropriately targeted therapies.

Perthera, Inc. Announces the Appointment of Gary L. Gregory as Chief Executive Officer, President and Board Member

Mr. Gregory is an experienced CEO and Board Member with 30 years of progressively challenging responsibilities in the MedTech Sector. His experience spans numerous companies and positions, including Executive Officer roles across several successful start-up companies, and leadership roles in Fortune 250 companies.

Perthera, UVA, and EVMS Team to Study the Implementation and Clinical Impact of a Next Generation Precision Oncology Platform for Pancreatic Cancer Patients

McLean, VA // Perthera, University of Virginia Health System (UVA) and Eastern Virginia Medical School (EVMS) Awarded $500,000 by Virginia Catalyst Multi-omic molecular comparison of primary versus metastatic pancreatic tumours.

ASCO Daily News: Genomic and Transcriptomic Profiling Finds Potential Predictors and Therapeutic Targets in Pancreatic Cancer

Dr. Mike Pishvaian discusses results from Perthera and PanCAN’s Know Your Tumor study, presented as Abstract 191 at ASCO GI 2019 in San Francisco, CA.

Perthera and the Pancreatic Cancer Action Network Publish Landmark Precision Medicine Study

Using real-world data from over 640 patients with pancreatic cancer, this landmark study demonstrated a 2.2 fold increase in progression-free survival for those being treated with a molecularly-matched therapy. Attached is a pdf of the press release.

Perthera to Host a Breakfast Symposium at the 2018 ASCO Annual Meeting

McLean, VA // Perthera, Inc., the leading Therapeutics Intelligence Company™, will be hosting a networking breakfast and educational session on Monday, June 4th from 6:30 – 7:30 a.m. for attendees of the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting. The breakfast symposium will be held in the Regency D ballroom of the Hyatt Regency McCormick Place, directly adjacent to the McCormick Place.

Perthera and Blue Faery Announce Their Partnership Against Liver Cancer

McLean, VA // Perthera, Inc., the leading Therapeutics Intelligence Company™, has announced its partnership with Blue Faery, the leading Hepatocellular Carcinoma advocacy group in the US, with the goal to provide liver cancer patients with therapeutic treatment options precisely matched to their individual cancers.


Contact Us